MGB Biopharma and Strathclyde to develop new MGB anti-infectives
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
List view / Grid view
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
17 November 2015 | By Victoria White
The study showed that two preliminary topical formulations of MGB-BP-3 were successful in killing approximately 60% of MRSA in a skin infection model...
10 September 2015 | By Victoria White
MGB Biopharma was one of three shortlisted finalists for the “Early Stage/ Risk Capital Deal of the Year” category which is awarded for a deal made by an early stage company...
2 June 2015 | By Victoria White
MGB Biopharma has developed a stable IV formulation of MGB-BP-3 for the treatment of Gram-positive hospital-acquired infections...